General
Preferred name
DIFLUPREDNATE
Synonyms
Myser ()
Epitopic ()
CM 9155 ()
Durezol ()
Difluprednato ()
W-6309 ()
W 6309 ()
P&D ID
PD009232
CAS
23674-86-4
Tags
available
prodrug
drug
Approved by
FDA
First approval
2008
Drug indication
Ocular pain
dry eye syndrome
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Difluprednate is a glucocorticoid receptor (GC receptor) agonist with a Ki of 0.78 nM. Difluprednate's active metabolite 21-deacetylated difluprednate (DFB) is a competitive agonist of GC receptors with a Ki of 0.061 nM. Difluprednate binds to GC receptors through metabolism to DFB, regulating the transcription of inflammatory mediator genes, thereby exerting anti-inflammatory activity. Difluprednate can be used for research related to ocular inflammation, such as postoperative inflammation, anterior uveitis, etc[1][2].
PRICE
33
DESCRIPTION
Difluprednate is a corticosteroid with antiinflammatory action.
(GtoPdb)
DESCRIPTION
Difluprednate (Myser)(Durezol) is a corticosteroid, approved for the treatment of post-operative ocular inflammation and pain.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
19
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
MedChem Express Bioactive Compound Library
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
34
Molecular Weight
508.23
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
1
Rotatable Bonds
6
Ring Count
4
Aromatic Ring Count
0
cLogP
3.52
TPSA
106.97
Fraction CSP3
0.7
Chiral centers
8.0
Largest ring
6.0
QED
0.55
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Indication
endogenous uveitis
Target
NR3C1
Phospholipase
MOA
Glucocorticoid Receptor agonist
Biosynthetic Origin
Terpenoid (Steroid)
Therapeutic Indication
Ocular Inflammation
Therapeutic Class
Antiinflammatory
Pathway
Metabolic Enzyme/Protease
Source data
